Pyramid, a large molecule drug product contract development and manufacturing organization (CDMO), appointed Amy Driver vice president of business development and Peter Buzy to the board of directors.

Driver joins Pyramid from Bionova Scientific, where she led the company’s business development efforts.

Buzy joins the company having previously served as President and CEO of Paragon Bioservices leading it to a successful sale to Catalent in 2019. Following the sale of Paragon, he served as the Chairman of Catalent’s Gene Therapy Division until 2021. He also currently serves on the boards of AeroSafe Global, Deka Biosciences, and LumaCyte, and is an Advisory Partner at NewSpring Healthcare.

“We are excited to have Amy and Pete join the Pyramid leadership team and the Pyramid Board, respectively, as we continue to invest in our team and resources to support our next phase of growth,” said Medhat Gorgy, CEO at Pyramid. “Amy’s proven ability to provide excellent service to her clients and industry expertise will help us advance our company’s expansion efforts. Pete’s operational and leadership expertise in the therapeutics industry, and his 30-plus year management track record will help guide our company’s strategic direction as we continue on our trajectory.”

“I am excited to join Pyramid at a key inflection point in the company’s growth story and look forward to supporting Pyramid and our clients as a part of the leadership team,” said Driver. “Pyramid’s reputation as a leader in the CDMO space and for providing best-in-class quality and service to its clients attracted me to the opportunity. I’m eager to partner with Medhat and the broader Pyramid organization to build on the company’s strong momentum.”

“Pyramid’s investments in its clients, facilities, employees, and leadership team positions the company well for continued growth alongside its current and new clients,” said Buzy. “The company has an impressive track record for quality and service, and I look forward to partnering with Medhat, the Pyramid team, Audax, and the rest of the board to navigate this next stage of growth.”